NewsBenzingaWells Fargo mantiene il rating Equal-Weight su Boston Scientific, abbassa il target di prezzo a 45 $ Wells Fargo mantiene il rating Equal-Weight su Boston Scientific, abbassa il target di prezzo a 45 $ Benzinga 2026.10.29 14:02 (GMT+0) Open on Benzinga Other news Swoosh and a Miss: Nike Investor Day Leaves Wall Street Cold-Footed Wall Street Says the AI Trade Is Over — ETF Investors Aren’t Acting Like It Citigroup Maintains Neutral on Westlake, Lowers Price Target to $65 Citigroup Maintains Neutral on LyondellBasell Industries, Lowers Price Target to $66 Caterpillar's 'Best-In-Class' Construction Business Is Getting Overlooked, Analyst Says How to Play NKE Stock as Nike Risks Becoming a Forever Turnaround Story